MedTrace Logo

Hypofractionated Radiotherapy for Prostate Cancer

NCT03851926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-02-10

No results posted yet for this study

Summary

Radiotherapy is a standard definitive treatment for men with localized prostate cancer.

Recent improvements in technology allow high doses of radiation to be delivered to the prostate in less days with lower doses to surrounding healthy tissues, trying to reduce side effects.

This study is being proposed to evaluate the use of moderate hypofractionated volumetric radiotherapy in localized prostate cancer patients and assessing treatment -related later adverse events using the CTCAE 4.0

Conditions

Interventions

RADIATION

Hypofractionated volumetric radiotherapy in 20 fractions

Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.

Sponsors & Collaborators

  • Consorci Sanitari de Terrassa

    lead OTHER

Principal Investigators

  • NICOLAS FELTES · Consorci Sanitari de Terrassa

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-05
Primary Completion
2021-10-05
Completion
2021-10-05

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03851926 on ClinicalTrials.gov